Who is eligible for clinical trial NCT01205815?

Participants must meet the protocol's inclusion criteria for Melanoma. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT01205815 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-09-15

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment (NCT01205815)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Vanderbilt-Ingram Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (3 items).

Location: Vanderbitl-Ingram Cancer Center — Nashville, Tennessee

Age range: 18 Years

🧪 Interventions in This Study

Tissue and blood collection (OTHER)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Pathologically-proven diagnosis of melanoma.
Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible.

Usually NOT eligible if any of the following apply:

Exclusion criteria
Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol.
Any patient unable or unwilling to provide consent.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Vanderbitl-Ingram Cancer Center — Nashville, Tennessee

📞 Contact the Study Coordinator

Phone: (800) 811-8480

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Melanoma

Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor — Portland, Oregon
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) — Houston, Texas
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 — La Jolla, California
In Vivo Real-time Detection of Circulating Melanoma Cells — Little Rock, Arkansas

Explore by condition: All Melanoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗